AstraZeneca, CSPC Partner on Next-Generation Obesity Therapies

AstraZeneca has strengthened its weight management and metabolic disease pipeline through a new strategic collaboration with CSPC Pharmaceuticals, targeting the development of multiple next-generation therapies for obesity and type 2 diabetes. The agreement covers eight programmes in total, including a clinical-ready asset, and provides AstraZeneca with access to CSPC’s advanced AI-driven peptide drug discovery capabilities and innovative once-monthly dosing technology.

Under the terms of the collaboration, the companies will initially advance four programmes that leverage CSPC’s proprietary artificial intelligence–enabled peptide discovery platform alongside its LiquidGel sustained-release technology. The LiquidGel platform is designed to support once-monthly injectable therapies, a dosing approach that could significantly improve patient adherence and long-term treatment outcomes in chronic metabolic conditions.

AstraZeneca will obtain exclusive global rights outside of China to CSPC’s once-monthly injectable weight management portfolio. This portfolio includes SYH2082, a long-acting GLP-1 receptor and GIP receptor dual agonist that is clinical-ready and expected to enter Phase I development, as well as three preclinical programmes with differentiated mechanisms of action. These assets are intended to deliver extended therapeutic benefits for people living with obesity and related metabolic disorders.

Sharon Barr, Executive Vice President and Head of BioPharmaceuticals R&D at AstraZeneca, said the collaboration adds important new assets that complement the company’s existing weight management strategy. She highlighted the potential of CSPC’s AI-enabled peptide discovery platform and proprietary dosing technology to address key challenges in obesity treatment, particularly adherence and convenience. According to Barr, the partnership represents a meaningful step toward building a portfolio of scalable and sustainable therapies that can support healthier lives for people with obesity and weight-related complications.

CSPC Pharmaceutical Group Chairman Dongchen Cai described the agreement as an expansion of the strategic relationship between the two companies into a high-impact therapeutic area. He noted that obesity and its associated comorbidities represent both a major global health challenge and a significant opportunity for innovation. Cai said the collaboration combines CSPC’s technology platforms with AstraZeneca’s global development, regulatory, and commercial capabilities to help deliver the next generation of weight management treatments worldwide.

Beyond the initial programmes, AstraZeneca retains optionality to pursue additional metabolic disease candidates using CSPC’s LiquidGel once-monthly dosing platform. The company also holds rights to apply this sustained-release technology across its internal development programmes, potentially broadening its use beyond obesity into other chronic conditions where less frequent dosing is preferred.

The deal complements AstraZeneca’s expanding weight management portfolio, which already includes elecoglipron, an oral small-molecule GLP-1 receptor agonist, AZD6234, a weekly injectable selective amylin receptor agonist, and AZD9550, a weekly injectable dual GLP-1/glucagon receptor agonist, alongside several preclinical assets. Together, these programmes reflect AstraZeneca’s multi-modality approach to addressing the biological complexity of obesity and tailoring treatments to individual patient needs.